Does Protease Inhibitor Inhibit Complement Activation Caused by the Immune Complex Associated with Islet Cell Surface Antibody?

Abstract

Sera containing islet cell surface antibody were obtained from seven children with insulin-dependent diabetes mellitus soon after the onset of disease. After incubation of ⁵¹Cr-labelled rat islet cells with islet cell surface antibody, human AB-type serum with or without nafamostat mesylate was added before further incubation. Radioactivity in the supernatant was measured to determine complement-dependent antibody-mediated cytotoxicity. Cytotoxicity in untreated sera [mean (± SD) 19.4 ± 4.0%] was significantly (P < 0.001) inhibited by ethyleneglycoltetraacetic acid (EGTA) (7.1 ± 4.9%), ethylenediaminetetraacetic acid (EDTA) (2.5 ± 0.9%) and nafamostat mesylate (2.8 ± 1.8%). Cytotoxicity of nafamostat mesylate-treated serum was significantly (P < 0.05) lower than that of EGTA-treated serum but not significantly different from that of EDTA-treated serum. There was no difference in cytotoxicity between nafamostat mesylate-treated and untreated, inactivated human serum. The results indicate that the protease inhibitor nafamostat mesylate completely inhibited the complement activation of the immune complex associated with islet cell surface antibody by the classical and alternative pathways.

Keywords

Nafamostat mesylate protease inhibitor insulin-dependent diabetes mellitus children complement activation islet cell surface antibody

Get full access to this article

View all access options for this article.

References

Okada

Sato

Miyaiy : Serum C3 and C4 levels and complement-dependent antibody-mediated cytotoxic activity of islet cell surface antibody in type 1 (insulin-dependent) diabetic children. Diabetologia 1987; 30: 869–873.

Lacy

Kostianovsky

: Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 1967; 16: 35–39.

Meda

Hooghe-Peters

Orci

: Monolayer cultures of adult pancreatic islet cells on osmotically disrupted fibroblasts. Diabetes 1980; 29: 497–500.

Lernmark

Sehlin

Taljedal

I-B

: Possible toxic effects of normal and diabetic patient serum of pancreatic B cells. Diabetologia 1978; 14: 25–31.

Aoyama

Ino

Ozeki

: Pharmacological studies of FUT-175, nafamostat mesylate. I. Inhibition of protease activity in in vitro and in vivo experiments. Jpn J Pharmacol 1984; 35: 203–227.